Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Yolla El‐Dakdouki"'
Autor:
Jean‐Marie Michot, Cyril Quivoron, Clémentine Sarkozy, Alina Danu, Julien Lazarovici, Khalil Saleh, Yolla El‐Dakdouki, Vincent Goldschmidt, Camille Bigenwald, Matteo Dragani, Rastislav Bahleda, Capucine Baldini, Julia Arfi‐Rouche, Patricia Martin‐Romano, Lambros Tselikas, Anas Gazzah, Antoine Hollebecque, Ludovic Lacroix, David Ghez, Veronique Vergé, Christophe Marzac, Sophie Cotteret, Wassila Rahali, Jean‐Charles Soria, Christophe Massard, Olivier A. Bernard, Peggy Dartigues, Valérie Camara‐Clayette, Vincent Ribrag
Publikováno v:
American Journal of Hematology. 98:645-657
Autor:
Jean-Marie, Michot, Cyril, Quivoron, Clémentine, Sarkozy, Alina, Danu, Julien, Lazarovici, Khalil, Saleh, Yolla, El-Dakdouki, Vincent, Goldschmidt, Camille, Bigenwald, Matteo, Dragani, Rastislav, Bahleda, Capucine, Baldini, Julia, Arfi-Rouche, Patricia, Martin-Romano, Lambros, Tselikas, Anas, Gazzah, Antoine, Hollebecque, Ludovic, Lacroix, David, Ghez, Veronique, Vergé, Christophe, Marzac, Sophie, Cotteret, Wassila, Rahali, Jean-Charles, Soria, Christophe, Massard, Olivier A, Bernard, Peggy, Dartigues, Valérie, Camara-Clayette, Vincent, Ribrag
Publikováno v:
American journal of hematology.
Advances in molecular profiling of newly diagnosed diffuse large cell B lymphoma (DLBCL) have recently refine genetic subgroups. Genetic subgroups remain undetermined at the time of relapse or refractory (RR) disease. This study aims to decipher gene
Autor:
Christophe Willekens, Romain Desmaris, Peggy Dartigues, Alina Danu, Julien Lazarovici, Christophe Fermé, David Ghez, Nathalie Ibrahim, Yolla El Dakdouki, Julien Rossignol, Pamela Abdayem, Jean M. Michot, Julia Arfi Rouche, Vincent Ribrag
Publikováno v:
European Journal of Haematology. 106:574-583
Objectives To evaluate the efficacy and tolerability of an attenuated immunochemotherapy regimen based on cytarabine, etoposide and dexamethasone plus rituximab (R-mini-CYVE) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
Autor:
Jean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, Alina Danu, Julien Lazarovici, Khalil Saleh, Yolla El-Dakdouki, Vincent Goldschmidt, Camille Bigenwald, Matteo Dragani, Rastislav Bahleda, Capucine Baldini, Julia Arfi-Rouche, Patricia Martin-Romano, Lambros Tselikas, Anas Gazzah, Antoine Hollebecque, Ludovic Lacroix, David Ghez, Veronique Vergé, Christophe Marzac, Sophie Cotteret, Wassila Rahali, Jean-Charles Soria, Christophe Massard, Olivier A. Bernard, Peggy Dartigues, Valérie Camara-Clayette, Vincent Ribrag
Publikováno v:
SSRN Electronic Journal.
Autor:
Mathilde Fusellier, Stéphane Champiat, Anne-Laure Voisin, Capucine Baldini, François-Xavier Danlos, Maxime Annereau, Olivier Lambotte, Christine Mateus, Caroline Robert, Aurélien Marabelle, C. Velter, Jean-Marie Michot, Khadija Cherif, Xavier Mariette, Yolla El Dakdouki
Publikováno v:
Annals of the rheumatic diseases. 78(7)
We read with interest the study of Kostine et al describing rheumatic immune-related adverse events (irAE), which occur in 6.6% of patients treated for cancer by anti-programmed death-(ligand) 1 (PDL1).1 These new adverse effects pose significant cha
Autor:
Anas Gazzah, Jean-Yves Scoazec, Sophie Postel-Vinay, Eric Deutsch, Antoine Hollebecque, Yolla El Dakdouki, Christophe Massard, Eric Solary, Ludovic Lacroix, Monica Arnedos, Etienne Rouleau, Jean-Pierre Armand, Loic Verlingue, Stefan Michiels, Fabrice Andre, Andrea Varga, Rastilav Balheda, Jean-Charles Soria, Capucine Baldini, Eric Angevin, Aurélien Marabelle, Thierry de Baere, Jean-Marie Michot, Olivier Mir
Publikováno v:
European journal of cancer (Oxford, England : 1990). 92
Introduction Therapeutic inhibition of the human epidermal receptor 3 (ERBB3, HER3) has been challenged by the low frequency of ERBB3 somatic alterations across cancer types. We have evaluated the clinical utility to use available inhibitors of the H
Autor:
Yolla El Dakdouki, Julia Salleron, Yoan Ditchi, Pernelle Lavaud, Marie-Christine Mathieu, Chloé Broudin, Patrick R. Benusiglio, Donia Lejri, Caroline Baynes, Marie Muller, Olivier Caron
Publikováno v:
The Breast Journal
The Breast Journal, 2019, 25 (1), pp.16-19. ⟨10.1111/tbj.13154⟩
The Breast Journal, 2019, 25 (1), pp.16-19. ⟨10.1111/tbj.13154⟩
International audience; BACKGROUND:Invasive lobular carcinoma (ILC) of the breast has epidemiological, molecular and clinical specificities, and should likely be considered a unique entity. As for genetic susceptibility, CDH1 germline mutations predi
Autor:
Patricia Kannouche, Nathalie Chaput, Said Aoufouchi, Laetitia Nebot-Bral, Stéphane Champiat, David Brandao, David Malka, Emmanuelle Despras, Olivier Caron, Aurélien Marabelle, Loic Verlingue, Alexandra Leary, Yolla El-Dakdouki, Etienne Rouleau
Publikováno v:
European journal of cancer (Oxford, England : 1990). 84
Immune checkpoint inhibitors have demonstrated unprecedented clinical activity in a wide range of cancers. Significant therapeutic responses have recently been observed in patients presenting mismatch repair-deficient (MMRD) tumours. MMRD cancers exh
Autor:
Adrien Allorant, Lambros Tselikas, Loic Verlingue, Yolla El Dakdouki, Christophe Massard, Cécile Jovelet, Stefan Michiels, Thierry Debaere, Fabrice Andre, Jean-Charles Soria, A. Hollebecque, Ludovic Lacroix, Gilles Vassal, Etienne Rouleau, Nathalie Auger
Publikováno v:
Cancer Research. 78:2953-2953
Background: MOSCATO 01 (NCT01566019) is a non-randomized single institution prospective clinical trial evaluating clinical benefit of integrating comprehensive molecular profiling into clinical practice to guide treatment in advanced cancers relapsin
Autor:
Andreea Varga, Jessica Menis, Jean-Marie Michot, Aurélien Marabelle, Yolla El-Dakdouki, Xavier Paoletti, Christophe Massard, Anas Gazzah, David Planchard, Saloomeh Rafie, Patricia Martin-Romano, Benjamin Besse, Vincent Ribrag, Capucine Baldini, Antoine Hollebecque, Rastislav Bahleda, Stéphane Champiat, Jean-Charles Soria
Publikováno v:
Cancer Research. 78:CT141-CT141
Background: Antiangiogenic drugs can synergize with immunotherapy in preclinical models. However some molecules have shown unacceptable levels of toxicity when combined with anti-PD-1. We aimed to determine the safety and activity of the nintedanib+p